| ACE | Angiotensin Converting Enzyme = Kininase II = Dipeptidyl Carboxypepti... |
|---|---|
| EIA | 1) Exercise Induced Asthma; 운동 유발성 천식 = EIB 2) Enzyme Immu... |
| ELISA | Enzyme-Linked Immuno-Sorbent Assay; 효소 면역법 |
| AAAE | amino acid activating enzyme |
| ACE | acetonitrile; acetylcholine esterase; acute cerebral encephalopathy; acute coronary event; adrenocor... |
| self-regulation | A three-stage strategy patients are taught to use in order to end risky health-associated behaviours such as smoking and overeating. 1. Self-monitoring (self-observation), the first stage in self-regulation involves the individual's deliberately attending to and recording his or her own behaviour; 2. Self-evaluation, the second stage, in which the individual assesses what was learned by self-monitoring, such as how often and where one smokes, and uses those observational data to establish health goals or criteria; 3. Self-reinforcement, the third stage, in which the individual rewards him/herself for each behavioural success on the road to that goal, thereby enhancing the chance of reaching it. (05 Mar 2000) |
|---|---|
| negative regulation | Negative feedback in biological systems mediated by allosteric regulatory enzymes. (18 Nov 1997) |
| down-regulation | <physiology> Development of a refractory or tolerant state consequent upon repeated administration of a pharmacologically or physiologically active substance. It is the process that decreases ligand and receptor interactions or reduces the responsiveness of a cell to a stimulus following first exposure. This is often accompanied by an initial decrease in affinity of receptors for the agent and a subsequent reduction in the number of available receptors expressed on the surface which can result from internalisation of the ligand:receptor complex or from decreased expression of the receptor. Classically the concept referred to hormone receptors but contemporary usage includes other cell surface receptors. (03 Jul 1999) |
| target regulation | <physiology> General term for an interaction between neurons and their targets by which target derived signals influence the differentiation of the innervating neurons. (18 Nov 1997) |
| facility regulation and control | Formal voluntary or governmental procedures and standards required of hospitals and health or other facilities to improve operating efficiency, and for the protection of the consumer. (12 Dec 1998) |
| feedback regulation | <physiology> Control mechanism that uses the consequences of a process to regulate the rate at which the process occurs: if, for example: the products of a reaction inhibit the reaction from proceeding (or slow down the rate of the reaction), then there is negative feedback, something that is very common in metabolic pathways. Positive feedback is liable to lead to exponential increase and may be explosively dangerous in some cases. Other examples are the action of voltage dependent sodium channels in generating action potentials and the activation of blood clotting factors V and VIII by thrombin. Without damping, feedback can lead to resonance (hunting) and oscillation in the system. (18 Nov 1997) |
| up-regulation | Opposite of down-regulation. (05 Mar 2000) |
| up-regulation (physiology) | Process that increases ligand/receptor interactions due to an increase in the number of available receptors. (12 Dec 1998) |
| acetyl-activating enzyme | A ligase that catalyses the reaction of acetate and CoA and ATP to form AMP, pyrophosphate, and acetyl-CoA. A key step in the activation of acetate. Synonym: acetate thiokinase, acetate-CoA ligase, acetyl-activating enzyme, acetyl-CoA synthetase. (05 Mar 2000) |
| acyl-activating enzyme | <enzyme> Fatty acid thiokinase (long-chain), a ligase forming acyl-CoA, AMP, and pyrophosphate from long-chain fatty acids, ATP, and coenzyme A. Activity is independent of phosphatidylcholine Registry number: EC 6.2.1.3 Synonym: acyl-activating enzyme, dodecanoyl-CoA synthetase, fatty acid thiokinase (long chain), acid-coenzyme a ligase, fatty acid-CoA ligase, acyl-CoA synthetase, acyl-CoA ligase, coash ligase, ciprofibroyl-CoA synthetase, pristanoyl-CoA synthetase, palmityl CoA synthetase, palmitoyl CoA synthetase, palmitoyl CoA ligase, fatty acyl-CoA synthetase, very long chain fatty acid acyl-CoA synthetase, vlcfa acyl-CoA synthetase, nafenopin-CoA ligase, palmitoyl-CoA synthase, faa2 gene product, faa2p protein, vlacs enzyme (26 Jun 1999) |
| adaptive enzyme | Inducible enzyme, an enzyme that can be detected in a growing culture of a microorganism, after the addition of a particular substance (inducer) to the culture medium, but was not detectable prior to the addition and can act on the inducer. A prototype is the beta-galactosidase of Escherichia coli, synthesised upon the addition of various galactosides, whether or not these are good substrates. Compare: constitutive enzyme. Synonym: adaptive enzyme. (05 Mar 2000) |
| allosteric enzyme | <biochemistry, chemistry> A regulatory enzyme whose activity is modified by the noncovalent binding of a particular metabolite at a site (the allosteric site) other than the active site. (09 Oct 1997) |
| amino acid activating enzyme | <enzyme> Enzymes catalyzing the formation of a specific aminoacyl-tRNA from an amino acid and adenosine 5'-triphosphate with the concomitant formation of adenosine 5'-monophosphate and pyrophosphate. Synonym: amino acid activating enzyme, aminoacyl-tRNA ligases. (05 Mar 2000) |
| angiotensin-converting enzyme | <enzyme> This hydrolase enzyme cleaves the decapeptide angiotensin I (biologically inactive) to form active angiotensin II by angiotensin-converting enzyme which removes a dipeptide (histidylleucine) from angiotensin I. Angiotensin II causes contraction of vascular smooth muscle and thus raises blood pressure and stimulates aldosterone release from the adrenal glands. Angiotensin is finally broken down by angiotensinases. Elevations in angiotensin converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy. The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels). Drugs that inhibit ACE are used to treat hypertension and congestive heart failure. See: angiotensin-converting enzyme inhibitor Acronym: ACE (12 Aug 2000) |
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |